Gene therapy may offer safer option for rare childhood disease

NCT ID NCT06149403

First seen Jan 07, 2026 · Last updated May 12, 2026 · Updated 22 times

Summary

This study tests a new gene therapy called OTL-203 for children with Hurler syndrome, a rare genetic disorder that damages organs and the brain. It compares the gene therapy to the current standard treatment, a stem cell transplant. The goal is to see if OTL-203 can improve survival and reduce serious complications like death, need for a rescue transplant, or severe cognitive and growth problems.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MPS-IH (HURLER SYNDROME) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Manchester University NHS Foundation Trust Blood and Marrow Transplant Programme, Royal Manchester Children's Hospital

    Manchester, M13 9WL, United Kingdom

  • Ospedale San Raffaele

    Milan, 20131, Italy

  • Princess Maxima Center

    Utrecht, 3584 CS, Netherlands

  • UMC Utrecht

    Utrecht, 3584 CX, Netherlands

  • University of Minnesota, Pediatrics

    Minneapolis, Minnesota, 55455, United States

Conditions

Explore the condition pages connected to this study.